Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.
Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.
复制标题
神经免疫药理学学会COVID-19虚拟研讨会。
DOI：
10.1007/s11481-021-10001-y
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Chang SL
中科院分区：
文献类型：
--
作者：
Kumar S;Pendyala G;Yelamanchili SV;Seth P;Maggirwar S;Bidlack JM;Chang SL
这份简短的报告收集了于2021年4月9日举行的神经免疫药理学学会（SNIP） COVID-19虚拟研讨会的程序和摘要。研讨会包括四个专题讨论会：专题讨论会一：2019冠状病毒病发病机制的分子方法；专题讨论会2:COVID-19的治疗和疫苗方法；专题讨论会3：早期职业研究者讲座；研讨会4：多样性和包容性SNIP委员会（DISC）计划：福祉和反思。研讨会还举办了四次关于COVID-19的特别讲座，以及来自国家酒精滥用和酒精中毒研究所（NIAAA）的资助机会；COVID-19和国家药物滥用研究所（NIDA）的资助机会；美国国立卫生研究院为早期职业研究者（ECI）提供的机会；以及SARS-CoV-2感染的神经和精神并发症。演讲者包括NIH官员、SNIP成员和非成员科学家，他们的摘要被提交并接受在内布拉斯加州大学医学中心通过Zoom网络研讨会主办的虚拟活动中。SNIP的官方期刊《神经免疫药理学杂志》（JNIP）将在主题专刊《新冠病毒的神经免疫药理学》中收录本次研讨会的部分论文和其他相关手稿。
This brief report collects the program and abstracts of the Society on NeuroImmune Pharmacology (SNIP) COVID-19 Virtual Workshop held on April 9, 2021. The workshop consisted of four symposia: Symposium 1: Molecular approaches to COVID-19 pathogenesis and underlying mechanisms; Symposium 2: Therapeutic and vaccine approaches to COVID-19; Symposium 3: Early Career Investigator talks; and Symposium 4: Diversity and Inclusion SNIP Committee (DISC) program: Well-being and reflections. The workshop also featured four special talks on COVID-19 and funding opportunities from the National Institute on Alcohol Abuse and Alcoholism (NIAAA); COVID-19 and funding opportunities from the National Institute on Drug Abuse (NIDA); opportunities from NIH for early career investigator (ECI) fellows; and neurologic and psychiatric complications of SARS-CoV-2 infection. Presenters included NIH officials, SNIP members, and non-member scientists whose abstracts were submitted and accepted for inclusion in the virtual event hosted by the University of Nebraska Medical Center via Zoom webinar. A special theme issue of SNIP's official journal, the Journal of Neuroimmune Pharmacology (JNIP), will collect select papers from the workshop along with other related manuscripts in a special theme issue titled "Neuroimmune Pharmacology of SARS-CoV-2.”